Parkinson's patients cope with daylight saving time.

Fetter D, Lefaucheur R, Borden A, Maltête D.

Rev Neurol (Paris). 2014 Feb;170(2):124-7. doi: 10.1016/j.neurol.2013.08.006.

Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.

Xie CL, Wang WW, Zhang SF, Yuan ML, Che JY, Gan J, Song L, Yuan WE, Liu ZG.

Sci Rep. 2014 Dec 16;4:7506. doi: 10.1038/srep07506.

Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson’s disease.

Cubo E, López Peña MJ, Diez-Feijo Varela E, Pérez Gil O, Garcia Gutierrez P, Araus González E, Prieto Tedejo R, Mariscal Pérez N, Armesto D.

J Neural Transm (Vienna). 2014 Feb;121(2):139-45.

Uncovering the role of the insula in non-motor symptoms of Parkinson's disease.

Christopher L, Koshimori Y, Lang AE, Criaud M, Strafella AP.

Brain. 2014 Aug;137(Pt 8):2143-54. doi: 10.1093/brain/awu084. Review.

Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Toy WA, Petzinger GM, Leyshon BJ, Akopian GK, Walsh JP, Hoffman MV, Vučković MG, Jakowec MW.

Neurobiol Dis. 2014 Mar;63:201-9. doi: 10.1016/j.nbd.2013.11.017.

A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease.

Troeung L, Egan SJ, Gasson N.

BMC Psychiatry. 2014 Jan 27;14:19. doi: 10.1186/1471-244X-14-19.

Mapping track density changes in nigrostriatal and extranigral pathways in Parkinson's disease.

Ziegler E, Rouillard M, André E, Coolen T, Stender J, Balteau E, Phillips C, Garraux G.

Neuroimage. 2014 Oct 1;99:498-508. doi: 10.1016/j.neuroimage.2014.06.033.

Test-retest validity of Parkinson's disease sleep scale 2nd version (PDSS-2).

Horváth K, Aschermann Z, Acs P, Deli G, Janszky J, Karádi K, Komoly S, Faludi B, Kovács N.

J Parkinsons Dis. 2014;4(4):687-91. doi: 10.3233/JPD-140459.

Humoral response against glial derived antigens in Parkinson's disease.

Papuć E, Kurzepa J, Kurys-Denis E, Grabarska A, Krupski W, Rejdak K.

Neurosci Lett. 2014 Apr 30;566:77-81. doi: 10.1016/j.neulet.2014.02.043.

A practical method for the detection of freezing of gait in patients with Parkinson's disease.

Kwon Y, Park SH, Kim JW, Ho Y, Jeon HM, Bang MJ, Jung GI, Lee SM, Eom GM, Koh SB, Lee JW, Jeon HS.

Clin Interv Aging. 2014 Oct 8;9:1709-19. doi: 10.2147/CIA.S69773.

Cortical volume and folding abnormalities in Parkinson's disease patients with pathological gambling.

Cerasa A, Salsone M, Nigro S, Chiriaco C, Donzuso G, Bosco D, Vasta R, Quattrone A.

Parkinsonism Relat Disord. 2014 Nov;20(11):1209-14. doi: 10.1016/j.parkreldis.2014.09.001.

JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.

Atack JR, Shook BC, Rassnick S, Jackson PF, Rhodes K, Drinkenburg WH, Ahnaou A, Te Riele P, Langlois X, Hrupka B, De Haes P, Hendrickx H, Aerts N, Hens K, Wellens A, Vermeire J, Megens AA.

ACS Chem Neurosci. 2014 Oct 15;5(10):1005-19. doi: 10.1021/cn5001606.

The neuropsychological assessment battery categories test as a measure of executive dysfunction in patients with Parkinson's disease and essential tremor: an exploratory study.

Benge J, Phillips-Sabol J, Phenis R.

Clin Neuropsychol. 2014;28(6):1008-18. doi: 10.1080/13854046.2014.950985.

Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Chou VP, Ko N, Holman TR, Manning-Boğ AB.

J Vis Exp. 2014 Jan 7;(83):e50960. doi: 10.3791/50960.

CNB-001, a novel pyrazole derivative mitigates motor impairments associated with neurodegeneration via suppression of neuroinflammatory and apoptotic response in experimental Parkinson's disease mice.

Jayaraj RL, Elangovan N, Dhanalakshmi C, Manivasagam T, Essa MM.

Chem Biol Interact. 2014 Sep 5;220:149-57. doi: 10.1016/j.cbi.2014.06.022.